StocksFundsScreenerSectorsWatchlists
FLGT

FLGT - Fulgent Genetics Inc Stock Price, Fair Value and News

21.69USD+0.06 (+0.28%)Market Closed

Market Summary

FLGT
USD21.69+0.06
Market Closed
0.28%

FLGT Alerts

  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

FLGT Stock Price

View Fullscreen

FLGT RSI Chart

FLGT Valuation

Market Cap

646.0M

Price/Earnings (Trailing)

-3.84

Price/Sales (Trailing)

2.23

EV/EBITDA

-3.73

Price/Free Cashflow

134.7

FLGT Price/Sales (Trailing)

FLGT Profitability

Operating Margin

36.12%

EBT Margin

-60.19%

Return on Equity

-14.81%

Return on Assets

-13.62%

Free Cashflow Yield

0.74%

FLGT Fundamentals

FLGT Revenue

Revenue (TTM)

289.2M

Rev. Growth (Yr)

4.14%

Rev. Growth (Qtr)

-16.75%

FLGT Earnings

Earnings (TTM)

-168.3M

Earnings Growth (Yr)

-435.89%

Earnings Growth (Qtr)

-874.4%

Breaking Down FLGT Revenue

Last 7 days

-1.3%

Last 30 days

-14.1%

Last 90 days

-27.8%

Trailing 12 Months

-29.3%

How does FLGT drawdown profile look like?

FLGT Financial Health

Current Ratio

6.96

FLGT Investor Care

Shares Dilution (1Y)

0.90%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023364.9M307.4M286.4M289.2M
2022953.4M869.8M702.6M619.0M
2021773.4M909.7M1.0B992.6M
202034.9M43.8M135.1M421.7M
201922.1M25.1M29.8M32.5M
201818.1M18.8M20.0M21.4M
201720.1M20.8M20.3M18.7M
201611.4M13.2M15.3M18.3M
20153.4M5.4M7.5M9.6M
20140001.3M

Tracking the Latest Insider Buys and Sells of Fulgent Genetics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 01, 2024
kim paul
sold (taxes)
-36,091
23.24
-1,553
cfo and treasurer
Mar 01, 2024
gao hanlin
sold (taxes)
-22,589
23.24
-972
chief scientific officer
Mar 01, 2024
xie jian
sold (taxes)
-34,372
23.24
-1,479
president and coo
Feb 26, 2024
xie jian
acquired
-
-
35,636
president and coo
Feb 26, 2024
xie jian
sold (taxes)
-134,134
24.26
-5,529
president and coo
Feb 26, 2024
hsieh ming
sold (taxes)
-437,893
24.26
-18,050
chief executive officer
Feb 26, 2024
kim paul
acquired
-
-
34,862
cfo and treasurer
Feb 26, 2024
hsieh ming
acquired
-
-
99,721
chief executive officer
Feb 26, 2024
gao hanlin
sold (taxes)
-79,815
24.26
-3,290
chief scientific officer
Feb 26, 2024
gao hanlin
acquired
-
-
30,377
chief scientific officer

1–10 of 50

Which funds bought or sold FLGT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-83.36
-54,561
11,969
-%
Mar 11, 2024
VANGUARD GROUP INC
added
1.61
3,674,250
40,942,100
-%
Mar 05, 2024
Fisher Asset Management, LLC
sold off
-100
-12,861
-
-%
Mar 04, 2024
VIMA LLC
new
-
3,469
3,469
0.01%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
97.51
3,148,470
5,921,460
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.91
21,409
321,566
-%
Feb 27, 2024
Beaird Harris Wealth Management, LLC
unchanged
-
32.00
434
-%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
15,000
186,000
-%
Feb 20, 2024
Aurora Investment Counsel
sold off
-100
-222,263
-
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
15.48
62,000
313,000
-%

1–10 of 45

Are Funds Buying or Selling FLGT?

Are funds buying FLGT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own FLGT
No. of Funds

Unveiling Fulgent Genetics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 23, 2024
blackrock inc.
12.7%
3,761,878
SC 13G/A
Jan 26, 2023
blackrock inc.
12.0%
3,527,782
SC 13G/A
Jan 20, 2023
blackrock inc.
12.0%
3,527,782
SC 13G
Nov 10, 2022
hsieh ming
29.5%
8,684,102
SC 13D/A
Jan 27, 2022
blackrock inc.
11.5%
3,421,251
SC 13G/A
Jan 26, 2022
blackrock inc.
11.5%
3,421,251
SC 13G/A
Jul 12, 2021
blackrock inc.
10.5%
3,057,315
SC 13G/A

Recent SEC filings of Fulgent Genetics Inc

View All Filings
Date Filed Form Type Document
Mar 27, 2024
ARS
ARS
Mar 27, 2024
DEF 14A
DEF 14A
Mar 27, 2024
DEFA14A
DEFA14A
Mar 12, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Feb 28, 2024
4
Insider Trading
Feb 28, 2024
10-K
Annual Report
Feb 28, 2024
4
Insider Trading

What is the Fair Value of FLGT?

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Cheap
or
Expensive?


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks

Peers (Alternatives to Fulgent Genetics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
184.1B
23.9B
1.92% 4.87%
38.82
7.71
-10.33% -33.23%
44.8B
3.7B
-4.47% 16.47%
53.05
12.25
8.72% 24.44%
43.2B
6.7B
9.35% 8.66%
34.96
6.42
-2.81% -6.58%
14.5B
9.3B
4.27% -4.49%
16.99
1.57
-6.38% -9.73%
13.8B
4.1B
11.27% 27.86%
29.14
3.35
3.86% -2.39%
12.4B
1.9B
4.38% 126.16%
43.86
6.58
29.17% 15.26%
12.1B
2.5B
1.85% -6.90%
-59.47
4.86
19.93% 67.26%
10.9B
1.1B
31.87% 65.38%
-25.12
10.09
31.99% 20.63%
MID-CAP
3.3B
918.7M
-13.78% -12.36%
284.21
3.64
45.66% 172.57%
2.2B
563.9M
-23.06% -38.26%
-4.56
3.88
25.45% 26.76%
SMALL-CAP
544.7M
280.3M
17.34% 2.80%
-2.86
1.94
-12.89% -148.37%
89.4M
31.2M
-3.36% -85.17%
-1.01
2.86
5.03% -1.81%
35.6M
9.2M
-24.43% -39.17%
-1.95
3.87
16.43% 46.89%
7.6M
9.0M
-21.88% -54.13%
-1.06
0.85
-53.31% 2.21%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Fulgent Genetics Inc News

Latest updates
Defense World • 2 hours ago
Defense World • 24 Mar 2024 • 06:25 am
MarketBeat • 23 Mar 2024 • 12:12 am
Seeking Alpha • 28 Feb 2024 • 08:00 am
Seeking Alpha • 21 Feb 2024 • 08:00 am

Fulgent Genetics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-16.7%70,50584,68767,85366,16867,704105,655125,341222,805320,268251,671227,868153,616359,429294,978101,71617,2657,7538,38710,3478,4245,370
Cost Of Revenue1.0%45,27644,84347,28147,35754,71759,56060,065-77,72562,13443,46635,85874,07551,77226,2617,7174,0573,6343,8853,6202,968
Gross Profit-36.7%25,22939,84420,57218,81112,98746,09565,276-242,543189,537184,402117,758285,354243,20675,4559,5483,6964,7536,4624,8042,402
Operating Expenses345.0%176,35039,63040,37043,63549,53945,74352,482-40,61038,67725,12918,86018,43217,29711,9326,9085,6105,1624,9534,5094,225
  S&GA Expenses3.3%10,50010,16110,72310,08310,2539,85910,866-7,9408,2006,0125,2195,0085,0815,0143,2601,5971,6351,6871,3041,272
  R&D Expenses19.4%11,95210,0149,6929,7828,5097,5076,905-5,9897,4646,0215,3125,4224,5763,1771,8491,9781,7951,7441,5741,424
EBITDA Margin-Infinity%-0.51*--------------------
Income Taxes-153.4%-10,85920,326-3,100-5,200-9,3864142,653-48,40047,14837,54523,58966,51358,57114,526-59934.00-38.0061.007.0013.00
Earnings Before Taxes-2216.6%-145,1966,860-14,700-21,049-33,4621,75713,752-201,978150,825159,76999,502267,204226,49863,9442,915-1,673-1601,698487-1,616
EBT Margin-176.5%-0.60*-0.22*-0.22*-0.11*0.30*0.52*0.67*0.70*0.64*0.68*0.73*0.72*---------
Net Income-874.4%-127,714-13,107-11,590-15,849-23,8321,71911,099-153,557104,339122,52279,812200,691166,30746,6383,321-1,956-2961,462331-1,908
Net Income Margin-158.8%-0.58*-0.22*-0.16*-0.07*0.23*0.39*0.50*0.53*0.48*0.51*0.55*0.54*---------
Free Cashflow122.4%11,8275,317-2,407-9,94128,48515,3417,868183,051183,05171,103148,79973,176---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-9.1%1,2351,3581,3551,3771,3861,4061,4621,4661,2791,2051,05099970024796.0089.0089.0061.0056.0056.0054.00
  Current Assets-7.6%50855052858162869767576561262356765952419641.0037.0037.0039.0035.0036.0040.00
    Cash Equivalents15.9%97.0084.0058.0066.0080.0016913935316521510015187.0053.002.009.0012.0021.009.005.007.00
  Net PPE-2.1%83.0085.0088.0079.0081.0082.0086.0069.0062.0060.0051.0047.0040.0017.006.006.006.006.006.006.006.00
  Goodwill-84.5%22.0014214214314312012151.0051.0049.0023.00----------
Liabilities5.7%10297.0091.0010811612415115311316012919813160.009.008.006.007.005.006.003.00
  Current Liabilities18.9%73.0061.0065.0082.0088.0010312814210514712219713058.007.006.004.004.003.003.003.00
Shareholder's Equity-9.7%1,1361,2591,2631,2691,2671,2811,3111,3131,1661,04492180256918787.0081.0083.0055.0051.0050.0051.00
  Retained Earnings-16.8%633761774786801825823812658553431351151-15.43-62.06-65.39-63.43-63.13-64.59-64.93-63.02
  Additional Paid-In Capital-2.4%502514506496487478504507502484482451418202148147146117116115114
Shares Outstanding-1.3%30.0030.0030.0030.0029.0030.0030.0030.0029.0030.0029.00----------
Minority Interest-189.8%-2.813.004.004.003.004.006.007.007.008.008.00----------
Float---629---978---1,600---191---39.00--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations45.8%14,93310,2409,737-7,90733,20720,77611,126188,41177,086152,20176,111233,179134,2569,415-4,4091,366-1163,9036751,055778
  Share Based Compensation4.9%11,43210,90210,32310,26510,0228,9728,0305,6165,0204,3743,5262,9623,0033,1501,080924938951737583598
Cashflow From Investing20.9%24,27020,078-1,096-4,354-92,59944,289-213,692688-140,259-34,793-155,005-216,491-318,767-1,404-2,405-3,862-36,0796,3443,211-2,522-2,536
Cashflow From Financing-480.0%-25,951-4,474-16,259-1,101-29,593-35,462-11,152-93413,154-2,98927,89347,347218,90342,571-59.00-16427,6391,1275.004.005.00
  Buy Backs940.1%22,8622,198--28,80334,70010,577----51316.00--46.00-----

FLGT Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Revenue$ 289,213$ 618,968$ 992,584
Cost of revenue184,757252,067215,533
Gross profit104,456366,901777,051
Operating expenses:   
Research and development41,44028,91024,219
Selling and marketing41,46738,91824,439
General and administrative88,999111,07450,732
Amortization of intangible assets7,8456,4971,708
Goodwill impairment loss120,234  
Restructuring costs 2,975 
Total operating expenses299,985188,374101,098
Operating (loss) income(195,529)178,527675,953
Interest and other income, net21,4445,4981,347
(Loss) income before income taxes and gain on equity-method investments(174,085)184,025677,300
Provision for income taxes1,15442,102174,795
(Loss) income before gain on equity-method investments(175,239)141,923502,505
Gain on equity-method investments  3,734
Net (loss) income from consolidated operations(175,239)141,923506,239
Net loss attributable to noncontrolling interests7,4141,4801,125
Net (loss) income attributable to Fulgent$ (167,825)$ 143,403$ 507,364
Net (loss) income per common share attributable to Fulgent:   
Basic$ (5.63)$ 4.76$ 17.25
Diluted$ (5.63)$ 4.63$ 16.38
Weighted-average common shares:   
Basic29,78430,09729,408
Diluted29,78430,96430,976

FLGT Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 97,473$ 79,506
Marketable securities326,681446,729
Trade accounts receivable, net of allowance for credit losses of $25,226 and $41,20551,13252,749
Other current assets32,55948,889
Total current assets507,845627,873
Marketable securities, long-term423,571326,648
Redeemable preferred stock investment20,43812,385
Fixed assets, net83,46481,353
Intangible assets, net143,053150,643
Goodwill, net22,055143,027
Other long-term assets34,90244,124
Total assets1,235,3281,386,053
Current liabilities  
Accounts payable15,36023,093
Accrued liabilities30,73724,981
Contract liabilities2,8743,199
Customer deposit22,70010,895
Investment margin loan 14,999
Notes payable, current portion1,1835,639
Other current liabilities1645,301
Total current liabilities73,01888,107
Unrecognized tax benefits5,9789,836
Deferred tax liabilities7,962 
Other long-term liabilities15,08418,235
Total liabilities102,042116,178
Commitments and contingencies (Note 8)
Stockholders’ equity  
Common stock, $0.0001 par value per share, 50,000 shares authorized, 32,416 shares issued and 29,653 shares outstanding and 31,248 shares issued and 29,438 shares outstanding33
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding 
Additional paid-in capital501,718486,585
Accumulated other comprehensive income (loss)1,205(20,903)
Retained earnings633,175801,000
Total Fulgent stockholders' equity1,136,1011,266,685
Noncontrolling interest(2,815)3,190
Total stockholders’ equity1,133,2861,269,875
Total liabilities and stockholders’ equity$ 1,235,328$ 1,386,053
FLGT
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
 CEO
 WEBSITEwww.fulgentgenetics.com
 EMPLOYEES1012

Fulgent Genetics Inc Frequently Asked Questions


What is the ticker symbol for Fulgent Genetics Inc? What does FLGT stand for in stocks?

FLGT is the stock ticker symbol of Fulgent Genetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fulgent Genetics Inc (FLGT)?

As of Wed Mar 27 2024, market cap of Fulgent Genetics Inc is 646.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FLGT stock?

You can check FLGT's fair value in chart for subscribers.

What is the fair value of FLGT stock?

You can check FLGT's fair value in chart for subscribers. The fair value of Fulgent Genetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fulgent Genetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FLGT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fulgent Genetics Inc a good stock to buy?

The fair value guage provides a quick view whether FLGT is over valued or under valued. Whether Fulgent Genetics Inc is cheap or expensive depends on the assumptions which impact Fulgent Genetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FLGT.

What is Fulgent Genetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, FLGT's PE ratio (Price to Earnings) is -3.84 and Price to Sales (PS) ratio is 2.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FLGT PE ratio will change depending on the future growth rate expectations of investors.